Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT
Lingvay I, Deanfield J, Kahn SE, et al.
Diabetes Care. Pub. online 22 Jun 2024.
Leggi
Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery
Samuels JM, Niswender KD, Roumie CL, et al.
Diabetes Obes Metab. Pub. online 27 Jun 2024.
Leggi
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: scandinavian cohort study
Engström A, Söderling J, Hviid A, et al.
Eur Heart J Cardiovasc Pharmacother. Pub. online 25 Jun 2024.
Leggi
Effect of fenofibrate on progression of diabetic retinopathy
Preiss D, Logue J, Sammons E, et al.
NEJM Evid. Pub. online 21 Jun 2024.
Leggi
Novel autologous dendritic cell therapy AVT001 for type 1 diabetes
Gaglia JL, Daley HL, Bryant NK, et al.
NEJM Evid. Pub. online 25 Jun 2024.
Leggi
Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
Aernouts C, Beldé SPW, Lambrechts J, et al.
Diabetes Obes Metab. Pub. online 25 Jun 2024.
Leggi
Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts
Saravanan P, Deepa M, Ahmed Z, et al.
Lancet Diabetes Endocrinol. Pub. online 24 Jun 2024.
Leggi
Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials
Verma S, Butler J, Borlaug BA, et al.
J Am Coll Cardiol. Pub. online 19 Jun 2024.
Leggi
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers
Van Rampelbergh J, Achenbach P, Leslie RD, et al.
BMC Med. Pub. online 21 Jun 2024.
Leggi
Pathophysiology from preconception, during pregnancy, and beyond
Hivert MF, Backman H, Benhalima K, et al.
Lancet. Pub. online 18 Jun 2024.
Leggi